BioNTech lowers 2026 sales outlook as COVID vaccine demand softens

BERLIN, Aug 4 (Reuters) - German vaccine maker BioNTech lowered its full year sales outlook range on Tuesday due to softer-than-expected COVID-19 vaccine demand and the timing of milestone-related revenues.

The company, which this week announced it had picked Guido Oelkers as its next CEO, now expects 2026 revenue between €1.6 billion and €1.9 billion ($1.84 billion-$2.19 billion) versus the €2 billion to €2.3 billion it had guided for in March.

($1 = 0.8688 euros)

(Reporting by Miranda Murray; Editing by Linda Pasquini)